

*U.S. Patent Application No. 10/823,506
First Amendment and Response to Office Action
Page 3*

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1-81. (Cancelled).

82. (Currently Amended) An isolated antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor or a polypeptide fragment thereof, wherein the GBS toxin receptor has at least about 86% identity to SEQ ID NO:8.

83. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody or the fragment thereof recognizes a polypeptide fragment of SEQ ID NO:4 or SEQ ID NO:8.

84. (Cancelled)

85. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the mammalian GBS toxin receptor is expressed on a surface of a cell.

86. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody is a monoclonal antibody or a polyclonal antibody.

87. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody or the fragment thereof is generated by a method comprising immunizing an animal with the mammalian GBS toxin receptor or the polypeptide fragment thereof.

*U.S. Patent Application No. 10/823,506
First Amendment and Response to Office Action
Page 4*

88. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody is a rabbit antibody or a mouse antibody.

89. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody recognizes an extracellular domain of the GBS toxin receptor or the polypeptide fragment thereof.

90-96. (Cancelled)

97. (Currently amended) A composition for detection of a GBS toxin receptor or a polypeptide fragment thereof, comprising a reagent for detection of the GBS toxin receptor or the polypeptide fragment thereof, wherein the GBS toxin receptor has at least about 86% identity to SEQ ID NO:8.

98. (Currently amended) The composition of Claim [18] 97, wherein the reagent for detection of the GBS toxin receptor or the polypeptide fragment thereof is an isolated antibody or a fragment thereof.

99. (Currently amended) The composition of Claim [18] 98, wherein the isolated antibody or the fragment thereof recognizes [a] the mammalian GBS toxin receptor or [a] the polypeptide fragment thereof.

100. (Currently amended) The composition of Claim [19] 98, wherein the isolated antibody or the fragment thereof recognizes [a] the polypeptide fragment of SEQ ID NO:4 or SEQ ID NO:8.

101. (Cancelled).

*U.S. Patent Application No. 10/823,506
First Amendment and Response to Office Action
Page 5*

102. (Currently amended) The composition of Claim [18] 97, wherein the GBS toxin receptor or the polypeptide fragment thereof is detected in a cell or a tissue of an animal or a human.

103. (Currently Amended) The isolated antibody or the fragment thereof of Claim [2] 82, wherein the isolated antibody or the fragment thereof is an inhibitor of binding of a GBS toxin to [a] the mammalian GBS toxin receptor.

104. (New) An isolated composition comprising an antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor or a polypeptide fragment thereof, wherein the GBS toxin receptor has at least about 86% identity to SEQ ID NO:8.

105. (New) The isolated composition of Claim 104, wherein the composition is isolated from an animal or a human.